Role of omega-3 fatty acids for prevention or treatment of perinatal depression

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 210-216

  Borja Hart, Nancy L ^a   Marino, Jehan ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Antenatal depression; Docosahexaenoic acid; Eicosapentaenoic acid; Omega 3 fatty acids; Perinatal depression; Postpartum depression

Indexed keywords

DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; VITAMIN;

ANTENAL DEPRESSION; ANTENATAL DEPRESSION; BECK DEPRESSION INVENTORY; CLINICAL EVALUATION; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; EDINBURGH POSTNATAL DEPRESSION SCALE; GASTROINTESTINAL SYMPTOM; HALITOSIS; HAMILTON SCALE; HEARTBURN; HUMAN; INSOMNIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; OPEN STUDY; PERINATAL DEPRESSION; PREGNANCY; PUERPERAL DEPRESSION; RATING SCALE; REVIEW; TASTE DISORDER;

CLINICAL TRIALS AS TOPIC; DEPRESSION; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; TIME FACTORS; TREATMENT OUTCOME;

EID: 75849157108     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.2.210     Document Type: Review

References (32)

1. Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. Perinatal depression: prevalence, screening, accuracy, and screening outcomes - summary. Available from www.ahrq.gov/clinic/epcsums/ peridepsum.htm. Accessed April 6, 2009.
2. American College of Obstetricians and Gynecologists. Clinical management guidelines for obstetrician-gynecologists: use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2008;111:1001-20.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000.
4. Gavin NI, Gaynes BN, Lohr KN, Meltzer-Brody S, Gartlehner G, Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005;106:1071-83.
5. Flynn HA, Blow FC, Marcus SM. Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetric practices. Gen Hosp Psychiatry 2006;28:289-95.
6. Kim HG, Mandell M, Crandall C, Kuskowski MA, Dieperink B, Buchberger RL. Antenatal psychiatric illness and adequacy of prenatal care in an ethnically diverse inner-city obstetric population. Arch Womens Ment Health 2006;9:103-7.
7. Monk C, Sloan RP, Myers MM, et al. Fetal heart rate reactivity differs by women's psychiatric status: an early marker for developmental risk? J Am Acad Child Adolesc Psychiatry 2004;43:283-90.
8. Alder J, Fink N, Bitzer J, Hösli I, Holzgreve W. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal, and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007;20:189-209.
9. Forray A, Ostroff RB. The use of electroconvulsive therapy in postpartum affective disorders. J ECT 2007;23:188-93.
10. Pearlstein T. Perinatal depression: treatment options and dilemmas. J Psychiatry Neurosci 2008;33:302-18.
11. U.S. Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs). Available from www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInfoPostmarketDrugSafetyInformatio/ucm12477.pdf. Accessed April 6, 2009.
12. GlaxoSmithKline. Use of Paxil CR or Paxil during pregnancy. Available from http://us.gsk.com/docs-pdf/media-news/mi-letter-paroxetine-pregnancy.pdf. Accessed August 15, 2008.
13. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. JAMA 2005;293:2372-83.
14. Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006;295:499-507.
15. McGregor JA, Allen KG, Harris MA, et al. The omega-3 story: nutritional prevention of preterm birth and other adverse pregnancy outcomes. Obstet Gynecol Surv 2001;56:S1-13.
16. Hornstra G, Al MD, van Houwelingen AC, Foremen-van Drongelen MM. Essential fatty acids in pregnancy and early human development. Eur J Obstet Gynecol Reprod Biol 1995;61:57-62.
17. Browne JC, Scott KM, Silvers KM. Fish consumption in pregnancy and omega-3 status after birth are not associated with postnatal depression. J Affect Disord 2006;90:131-9.
18. Llorente AM, Jensen CL, Voigt RG, Fraley JK, Berretta MC, Heird WC. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 2003;188:1348-53.
19. Hibbeln JR. Seafood consumption, the DHA content of mothers' milk and prevalence of postpartum depression: a cross-national, ecological analysis. J Affect Disord 2002;69:15-29.
20. De Vriese SR, Christophe AB, Maes M. Lowered serum n-3 polyunsaturated fatty acid (PUFA) levels predict the occurrence of postpartum depression: further evidence that lowered n-PUFAs are related to major depression. Life Sci 2003;73:3181-7.
21. Otto SJ, de Groot RH, Hornstra G. Increased risk of postpartum depressive symptoms is associated with slower normalization after pregnancy of the functional docosahexaenoic acid status. Prostaglandins Leukot Essent Fatty Acids 2003;69:237-43.
22. Freeman MP, Hibbeln JR, Wisner KL, Watchman M, Gelenberg AJ. An open trial of omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatrica 2006:18:21-4.
23. Su KP, Huang SY, Chiu TH, et al. Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:644-51.
24. Freeman MP, Davis M, Sinha P, Wisner KL, Hibbeln JR, Gelenberg AJ. Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord 2008;110:142-8.
25. Rees AM, Austin MP, Parker GB. Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust N Z J Psychiatry 2008;42:199-205.
26. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman W, Gelenberg AJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 2006;113:31-5.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiat 1960;23:56-62.
28. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh postnatal depression scale. Br J Psychiatry 1987;150:782-6.
29. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961;4:561-71.
30. Guy W. ECDEU assessment manual for psychopharmacology. U.S. Department of Health, Education, and Welfare publication ADM 76-338. Rockville, MD: National Institute of Mental Health, 1976.
31. Marangell LB, Martinez JM, Zboyan HA, Chong H, Puryear LJ. Omega-3 fatty acids for the prevention of postpartum depression: negative data from a preliminary, open-label pilot study. Depress Anxiety 2004;19:20-3.
32. Freeman MP, Sinha P. Tolerability of omega-3 fatty acid supplements in perinatal women. Prostaglandins Leukot Essent Fatty Acids 2007;77:203-8.